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Advance Access publication on 3 October 2008 Use of fresh frozen plasma to enhance the therapeutic action of rituximab Sir, I was very pleased to read the recent report by Dr Klepfish and his colleagues (published online July 23, 2008) in which they demonstrated that fresh frozen plasma could be used to dramatically enhance the therapeutic action of rituximab in the treatment of chronic lymphocytic leukemia (CLL). In this article, they noted that in 2004 our laboratory reported, in the Journal of Immunology 1 that in CLL 'complement may be rapidly depleted as a consequence of RTX therapy.' However, the present report by Dr Klepfish and colleagues did not acknowledge that in our 2004 paper we also made the following statement, 'Therefore, we suggest that if complement is required to promote killing of RTX-opsonized cells, then use of C2, or compatible fresh frozen plasma as a complement source, may enhance the action of RTX in patients with reduced or depleted complement levels.' We are very pleased to see that the treatment paradigm we first proposed more than 4 years ago appears to be validated by the work of Dr Klepfish and colleagues. Incidentally, we were not aware of this study when we decided to treat our first patient with advanced CLL resistant to multiple treatment modalities including fludarabine and rituximab, with a Correspondence 991
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